What’s wrong with the peptide?

Regeneron had said in December that Sanofi had withdrawn its application for marketing approval for Zaltrap and was planning to resubmit it early this year.

"The study did not meet the pre-specified criterion of improvement in overall survival," Sanofi said, referring to a Phase III study of Zaltrap, also known as aflibercept, in treating prostate cancer.

Well, of course we know what is wrong – the whole paradigm of specific targeting in oncology does not hold water. Otherwise we can state that something wrong with evidence based medicine J…